Abstract
Background/Aims: Kidney disease patients experience declining calcitriol levels and develop secondary hyperparathyroidism (SHPT). Animal models of uremia based on 5/6 nephrectomy (NTX) do not consistently reproduce this calcitriol deficiency. We developed an animal model, the NTX Cyp27b1-null mouse, which completely lacks endogenous calcitriol, and examined the suitability of this model for evaluation of treatment with vitamin D analogs in uremia. Methods: NTX was performed at 2 months of age. One week post-NTX, animals were treated for 4 weeks with vehicle; doxercalciferol at 30, 100 or 300 pg/g body weight (b.w.); or paricalcitol at 100, 300 or 1,000 pg/g b.w. by gavage 3 times per week. Results: Serum blood urea nitrogen and creatinine were elevated. Vehicle-treated NTX null mice had hypocalcemia and SHPT. Doxercalciferol at 100 or 300 pg/g b.w. normalized serum calcium and parathyroid hormone (PTH) levels. Paricalcitol at 300 or 1,000 pg/g normalized serum calcium, but PTH levels remained elevated. Osteomalacia was corrected by 100 pg/g b.w. of doxercalciferol or 1,000 pg/g b.w. of paricalcitol. The highest dose of doxercalciferol, but not of paricalcitol, significantly reduced osteitis fibrosa. Conclusion: Our results reveal the differential efficacy of doxercalciferol and paricalcitol in this novel animal model incorporating both calcitriol deficiency and renal insufficiency.
Journal Section:
Original Paper
References
1.
Elder G: Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002;17:2094–2105.
[PubMed]
2.
Martinez I, Saracho R, Montenegro J, Llach F: The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997;29:496–502.
[PubMed]
3.
Salusky IB: Are new vitamin D analogues in renal bone disease superior to calcitriol? Pediatr Nephrol 2005;20:393–398.
4.
Llach F, Fernandez E: Overview of renal bone disease: causes of treatment failure, clinical observations, the changing pattern of bone lesions, and future therapeutic approach. Kidney Int Suppl 2003;S113–S119.
5.
Slatopolsky E, Gonzalez E, Martin K: Pathogenesis and treatment of renal osteodystrophy. Blood Purif 2003;21:318–326.
[PubMed]
6.
Steddon SJ, Fan SL, Cunningham J: New prospects for the management of renal bone disease. Nephron Clin Pract 2005;99:c1–c7.
7.
Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478–1483.
[PubMed]
8.
Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695–701.
[PubMed]
9.
Raggi P, Kleerekoper M: Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3:836–843.
10.
Sjoden G, Smith C, Lindgren U, DeLuca HF: 1 alpha-hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat. Proc Soc Exp Biol Med 1985;178:432–436.
11.
Slatopolsky E, Finch J, Ritter C, Denda M, Morrissey J, Brown A, DeLuca H: A new analog of calcitriol, 19-Nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995;26:852–860.
[PubMed]
12.
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1–S201.
[PubMed]
13.
Drueke TB: Which vitamin D derivative to prescribe for renal patients. Curr Opin Nephrol Hypertens 2005;14:343–349.
14.
Frazao JM, Chesney RW, Coburn JW: Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1alphaD2 Study Group. Nephrol Dial Transplant 1998;13(suppl 3):68–72.
15.
Frazao JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW: Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000;36:550–561.
[PubMed]
16.
Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J: 19-Nor-1-alpha-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998;9:1427–1432.
[PubMed]
17.
Maung HM, Elangovan L, Frazao JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW: Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001;37:532–543.
[PubMed]
18.
Knutson JC, LeVan LW, Valliere CR, Bishop CW: Pharmacokinetics and systemic effect on calcium homeostasis of 1 alpha,24-dihydroxyvitamin D2 in rats. Comparison with 1 alpha,25-dihydroxyvitamin D2, calcitriol, and calcipotriol. Biochem Pharmacol 1997;53:829–837.
19.
St-Arnaud R, Arabian A, Yu VW, Akhouayri O, Knutson JC, Strugnell SA: 1alpha,24(S)(OH)2D2 normalizes bone morphology and serum parathyroid hormone without hypercalcemia in 25-hydroxyvitamin D-1-hydroxylase (CYP27B1)-deficient mice, an animal model of vitamin D deficiency with secondary hyperparathyroidism. J Endocrinol Invest 2008;31:711–717.
20.
Behets GJ, Dams G, Vercauteren SR, Damment SJ, Bouillon R, De Broe ME, D’Haese PC: Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol 2004;15:2219–2228.
[PubMed]
21.
Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E: A new analog of 1,25-(OH)2D3, 19-Nor-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997;30:105–112.
22.
Dardenne O, Prud’homme J, Arabian A, Glorieux FH, St-Arnaud R: Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 2001;142:3135–3141.
[PubMed]
23.
Dardenne O, Prud’homme J, Hacking SA, Glorieux FH, St-Arnaud R: Correction of the abnormal mineral ion homeostasis with a high-calcium, high-phosphorus, high-lactose diet rescues the PDDR phenotype of mice deficient for the 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1). Bone 2003;32:332–340.
24.
Dickson GR: Methods of calcified tissue preparation. New York, Elsevier, 1984.
25.
Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR: Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 1987;2:595–610.
[PubMed]
26.
Hernandez JD, Wesseling K, Salusky IB: Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy. Semin Dial 2005;18:290–295.
27.
Lotinun S, Sibonga JD, Turner RT: Evidence that the cells responsible for marrow fibrosis in a rat model for hyperparathyroidism are preosteoblasts. Endocrinology 2005;146:4074–4081.
28.
Dardenne O, Prudhomme J, Hacking SA, Glorieux FH, St-Arnaud R: Rescue of the pseudo-vitamin D deficiency rickets phenotype of CYP27B1-deficient mice by treatment with 1,25-dihydroxyvitamin D3: biochemical, histomorphometric, and biomechanical analyses. J Bone Miner Res 2003;18:637–643.
29.
Martin KJ, Gonzalez EA: Strategies to minimize bone disease in renal failure. Am J Kidney Dis 2001;38:1430–1436.
[PubMed]
30.
Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of bone disease in end-stage renal failure – an evolving disorder. Kidney Int 1993;43:436–442.
[PubMed]
31.
Malluche HH, Monier-Faugere MC: Hyperphosphatemia: pharmacologic intervention yesterday, today and tomorrow. Clin Nephrol 2000;54:309–317.
[PubMed]
32.
Westenfeld R, Schafer C, Smeets R, Brandenburg VM, Floege J, Ketteler M, Jahnen-Dechent W: Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant 2007;22:1537–1546.
[PubMed]
33.
Richard-Fiardo P, Payen E, Chevre R, Zuber J, Letrou-Bonneval E, Beuzard Y, Pitard B: Therapy of anemia in kidney failure, using plasmid encoding erythropoietin. Hum Gene Ther 2008;19:331–342.
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.
